Impaired coupling of muscarinic M1 receptors to G-proteins in the neocortex is associated with severity of dementia in Alzheimer's disease

Neurobiology of Aging

Volumn 27, Issue 9, 2006, Pages 1216-1223

  Tsang, Shirley W Y ^a   Lai, Mitchell K P ^b,c   Kirvell, Sara ^c   Francis, Paul T ^c   Esiri, Margaret M ^d   Hope, Tony ^d   Chen, Christopher P L H ^a,e   Wong, Peter T H ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

Author keywords

Alzheimer's disease; Cognition; G proteins; Muscarinic receptors

Indexed keywords

CHOLINE ACETYLTRANSFERASE; GUANINE NUCLEOTIDE BINDING PROTEIN; MUSCARINIC M1 RECEPTOR; NUCLEOTIDE BINDING PROTEIN;

AGE; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CLINICAL FEATURE; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME SUBSTRATE; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; LONGITUDINAL STUDY; MALE; MOLECULAR MECHANICS; NEOCORTEX; NEUROCHEMISTRY; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN TARGETING; RECEPTOR DENSITY; TEMPORAL CORTEX;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; BRAIN CHEMISTRY; CHOLINE O-ACETYLTRANSFERASE; COGNITION DISORDERS; DEMENTIA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GTP-BINDING PROTEINS; HUMANS; MALE; MUSCARINIC ANTAGONISTS; NEOCORTEX; PIRENZEPINE; POSTMORTEM CHANGES; PROTEIN BINDING; PSYCHIATRIC STATUS RATING SCALES; RECEPTOR, MUSCARINIC M1; TRITIUM;

EID: 33746210128     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2005.07.010     Document Type: Article

References (37)

1. Anagnostaras S.G., Murphy G.G., Hamilton S.E., Mitchell S.L., Rahnama N.P., Nathanson N.M., et al. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci 6 (2003) 1-58
2. Braak H., and Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 82 (1991) 239-259
3. Caulfield M.D. Muscarinic receptors-characterization, coupling and function. Pharmacol Ther 58 (1993) 319-379
4. 50) of an enzymatic reaction. Biochem Pharmacol 22 (1973) 3099-3108
5. DeCarli C., Mungas D., Harvey D., Reed B., Weiner M., Chui H., et al. Memory impairment, but not cerebrovascular disease, predicts progression of MCI to dementia. Neurology 63 (2004) 220-227
6. Etcheberrigaray R., Tan M., Dewachter I., Kuiperi C., Van der Auwera I., Wera S., et al. Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. Proc Natl Acad Sci USA 101 (2004) 11141-11146
7. 3H]-PIP2 hydrolysis in Alzheimer's disease. Life Sci 53 (1993) PL439-PL444
8. Flynn D.D., Ferrari-DiLeo G., Levey A.I., and Mash D.C. Differential alterations in muscarinic receptor subtypes in Alzheimer's disease: implications for cholinergic-based therapies. Life Sci 56 (1995) 869-876
9. Flynn D.D., Weinstein D.A., and Mash D.C. Loss of high-affinity agonist binding to M1 muscarinic receptors in Alzheimer's disease: implications for the failure of cholinergic replacement therapies. Ann Neurol 29 (1991) 256-262
10. Folstein M.F., Folstein S.E., and McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975) 189-198
11. Fonnum F. A rapid radiochemical method for the determination of choline acetyltransferase. J Neurochem 24 (1975) 407-409
12. Francis P.T., Palmer A.M., Sims N.R., Bowen D.M., Davison A.N., Esiri M.M., et al. Neurochemical studies of early-onset Alzheimer's disease possible influence on treatment. N Engl J Med 313 (1985) 7-11
13. Francis P.T., Palmer A.M., Snape M., and Wilcock G.K. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 66 (1999) 137-147
14. García-Jiménez A., Cowburn R.F., Ohm T.G., Lasn H., Winblad B., Bogdanovic N., et al. Loss of stimulatory effect of guanosine triphosphate on [35S]GTPgS binding correlates with Alzheimer's disease neurofibrillary pathology in entorhinal cortex and CA1 hippocampal subfield. J Neurosci Res 67 (2002) 388-398
15. García-Jiménez A., Fastbom J., Ohm T.G., and Cowburn R.F. G-protein a-subunit levels in hippocampus and entorhinal cortex of brains staged for Alzheimer's disease neurofibrillary and amyloid pathologies. Neuroreport 14 (2003) 1523-1527
16. Hagan J.J., Jansen J.H., and Broekkamp C.L. Blockade of spatial learning by the M1 muscarinic antagonist pirenzepine. Psychopharmacology (Berl) 93 (1987) 470-476
17. Hardy J.A., Wester P., Winblad B., Gezelius C., Bring G., and Eriksson A. The patients dying after long terminal phase have acidotic brains; implications for biochemical measurements on autopsy tissue. J Neural Transm 61 (1985) 253-264
18. Hope T., Keene J., Fairburn C.G., Jacoby R., and McShane R. Natural history of behavioural changes and psychiatric symptoms in Alzheimer's disease. A longitudinal study. Br J Psychiatry 174 (1999) 39-44
19. Hope T., Keene J., Gedling K., Cooper S., Fairburn C., and Jacoby R. Behaviour changes in dementia. 1. Point of entry data of a prospective study. Int J Geriatr Psychiatry 12 (1997) 1062-1073
20. Jobst K.A., Smith A.D., Szatmari M., Esiri M.M., Jaskowski A., Hindley N., et al. Rapidly progressing atrophy of medial temporal lobe in Alzheimer's disease. Lancet 343 (1994) 829-830
21. Jope R.S. Cholinergic muscarinic receptor signaling by the phosphoinositide signal transduction system in Alzheimer's disease. J Alzheimers Dis 1 (1999) 231-247
22. Lai M.K., Lai O.F., Keene J., Esiri M.M., Francis P.T., Hope T., et al. Psychosis of Alzheimer's disease is associated with elevated muscarinic M2 binding in the cortex. Neurology 57 (2001) 805-811
23. Lu W.Y., Xiong Z.G., Lei S., Orser B.A., Dudek E., Browning M.D., et al. G-protein-coupled receptors act via protein kinase C and Src to regulate NMDA receptors. Nat Neurosci 2 (1999) 331-338
24. Mash D.C., Flynn D.D., and Potter L.T. Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science 228 (1985) 1115-1117
25. Masliah E., Cole G.M., Hansen L.A., Mallory M., Albright T., Terry R.D., et al. Protein kinase C alteration is an early biochemical marker in Alzheimer's disease. J Neurosci 11 (1991) 2759-2767
26. McBain C.J., and Mayer M.L. N-Methyl-d-aspartic acid receptor structure and function. Physiol Rev 74 (1994) 723-760
27. McPherson G.A. Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC. J Pharmacol Methods 14 (1985) 213-228
28. Mesulam M. The cholinergic lesion of Alzheimer's disease: pivotal factor or side show?. Learn Mem 11 (2004) 43-49
29. Minger S.L., Esiri M.M., McDonald B., Keene J., Carter J., Hope T., et al. Cholinergic deficits contribute to behavioral disturbance in patients with dementia. Neurology 55 (2000) 1460-1467
30. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41 (1991) 479-486
31. Morris J.C., Storandt M., Miller J.P., McKeel D.W., Price J.L., Rubin E.H., et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 58 (2001) 397-405
32. Perry E.K., Blessed G., Tomlinson B.E., Perry R.H., Crow T.J., Cross A.J., et al. Neurochemical activities in human temporal lobe related to aging and Alzheimer-type changes. Neurobiol Aging 2 (1981) 251-256
33. Perry E.K., Gibson P.H., Blessed G., Perry R.H., and Tomlinson B.E. Neurotransmitter enzyme abnormalities in senile dementia Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J Neurol Sci 34 (1977) 247-265
34. Potter P.E., Gaughan C., and Assouline Y. Lesion of septal-hippocampal neurons with 192 IgG-saporin alters function of M1 muscarinic receptors. Neuropharmacology 38 (1999) 579-586
35. Roldan G., Bolanos-Badillo E., Gonzalez-Sanchez H., Quirarte G.L., and Prado-Alcala R.A. Selective M1 muscarinic receptor antagonists disrupt memory consolidation of inhibitory avoidance in rats. Neurosci Lett 230 (1997) 93-96
36. Whitehouse P.J., Price D.L., Struble R.G., Clark A.W., Coyle J.T., and Delon M.R. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 215 (1982) 1237-1239
37. Wilcock G.K., Esiri M.M., Bowen D.M., and Smith C.C. Alzheimer's disease correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities. J Neurol Sci 57 (1982) 407-417